Generic Advair HFA Availability
Last updated on Jun 11, 2025.
See also: Generic Advair Diskus
Advair HFA is a brand name of fluticasone/salmeterol, approved by the FDA in the following formulation(s):
ADVAIR HFA (fluticasone propionate; salmeterol xinafoate - aerosol, metered;inhalation)
-
Manufacturer: GLAXO GRP LTD
Approval date: June 8, 2006
Strength(s): 0.045MG/INH;EQ 0.021MG BASE/INH [RLD], 0.115MG/INH;EQ 0.021MG BASE/INH [RLD], 0.23MG/INH;EQ 0.021MG BASE/INH [RLD]
Is there a generic version of Advair HFA available?
An Authorized Generic version of Advair HFA has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.
List of authorized generic versions:
- fluticasone propionate and salmeterol xinafoate RESPIRATORY (INHALATION) AEROSOL, METERED 45; 21 ug/1; ug
Prasco Laboratories
NDC Code: 669930086 - fluticasone propionate and salmeterol xinafoate RESPIRATORY (INHALATION) AEROSOL, METERED 115; 21 ug/1; ug
Prasco Laboratories
NDC Code: 669930087 - fluticasone propionate and salmeterol xinafoate RESPIRATORY (INHALATION) AEROSOL, METERED 230; 21 ug/1; ug
Prasco Laboratories
NDC Code: 669930088
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Advair HFA. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
More about Advair HFA (fluticasone / salmeterol)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Reviews (11)
- Drug images
- Side effects
- Dosage information
- During pregnancy
- Support group
- Drug class: bronchodilator combinations
- En español
Patient resources
Other brands
Advair Diskus, Wixela Inhub, AirDuo Respiclick, AirDuo Digihaler
Professional resources
Other brands
Advair Diskus, Wixela Inhub, AirDuo Respiclick, AirDuo Digihaler
Related treatment guides
Related/similar drugs
Breztri Aerosphere
Breztri (budesonide/glycopyrrolate/formoterol fumarate) is a combination inhaler used for the ...
Xolair
Xolair injection (omalizumab) is used to help improve allergic asthma, nasal polyps, and chronic ...
Dupixent
Dupixent is used to treat eczema, eosinophilic or oral-corticosteroid-dependent asthma, chronic ...
Symbicort
Symbicort (budesonide and formoterol) is used to prevent bronchospasm in people with asthma or ...
Ventolin
Ventolin is used for asthma, acute, asthma, maintenance, bronchiectasis, bronchospasm prophylaxis ...
Ventolin HFA
Ventolin HFA (albuterol) is used to treat or prevent breathing problems in patients who have asthma ...
Breo Ellipta
Breo Ellipta (fluticasone and vilanterol) is used to prevent airflow obstruction or bronchospasm in ...
Spiriva
Spiriva (tiotropium) is used to prevent bronchospasm in people with bronchitis, emphysema, or COPD ...
Xopenex
Xopenex is a short-acting bronchodilator used to treat or prevent bronchospasm in asthma and other ...
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
